LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Strona główna・Stock List・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

4.32 -5.68

Buy Sell

Overview

Share price change

24h

Current

Min

4.31

Max

4.37

Key metrics
By Trading Economics
Income	9.6M -162M
Sales	-14M 5.2M
EPS	-0.36
Profit margin	-3,135.324
Employees	800
EBITDA	6.4M -141M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+54.04% upside

Market Stats
By TradingEconomics
Market Cap	138M 2.5B
Previous open	10
Previous close	4.32

News Sentiment

By Acuity

50%

158 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

4.15 / 4.75 Support & Resistance

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

14 gru 2025, 22:53 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 gru 2025, 00:04 UTC

Acquisitions, Mergers, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 gru 2025, 23:46 UTC

Market Talk

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 gru 2025, 23:36 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 gru 2025, 22:38 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 gru 2025, 22:02 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 gru 2025, 22:01 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 gru 2025, 22:01 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 gru 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 gru 2025, 22:00 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 gru 2025, 21:59 UTC

Acquisitions, Mergers, Takeovers

Fortescue to Acquire Remaining 64% of Alta Copper

14 gru 2025, 17:00 UTC

Earnings

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 gru 2025, 08:30 UTC

Acquisitions, Mergers, Takeovers

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 gru 2025, 16:48 UTC

Acquisitions, Mergers, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 gru 2025, 08:00 UTC

Acquisitions, Mergers, Takeovers

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 gru 2025, 07:00 UTC

Acquisitions, Mergers, Takeovers

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 gru 2025, 00:24 UTC

Acquisitions, Mergers, Takeovers

Want a Piece Of SpaceX? -- Barrons.com

12 gru 2025, 23:49 UTC

Acquisitions, Mergers, Takeovers

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 gru 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 gru 2025, 22:32 UTC

Earnings

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 gru 2025, 20:45 UTC

Earnings

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 gru 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 gru 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 gru 2025, 19:23 UTC

Earnings

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 gru 2025, 18:35 UTC

Acquisitions, Mergers, Takeovers

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 gru 2025, 18:33 UTC

Acquisitions, Mergers, Takeovers

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 gru 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 gru 2025, 17:49 UTC

Earnings

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 gru 2025, 17:34 UTC

Acquisitions, Mergers, Takeovers

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

54.04% upside

12 Months Forecast

Average 6.67 USD 54.04%

High 8 USD

Low 5 USD

Based on 5 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Recursion Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

158 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.